| Risk | High |
|---|---|
| Min SIP Amount | ₹100 |
| Expense Ratio | 1.45% |
| NAV | ₹16.37 (23 Oct 2020) |
|---|---|
| Fund Started | 15 Jun 2018 |
| Fund Size | ₹1,988 Cr |
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Cipla Ltd. | Healthcare | Equity | 9.6% |
| Sun Pharmaceutical Inds. Ltd. | Healthcare | Equity | 9.3% |
| Alkem Laboratories Ltd. | Healthcare | Equity | 5.4% |
| Dr. Reddy's Laboratories Ltd. | Healthcare | Equity | 5.2% |
| Divi's Laboratories Ltd. | Healthcare | Equity | 4.6% |
| Lupin Ltd. | Healthcare | Equity | 4.5% |
| Tata Chemicals Ltd. | Chemicals | Equity | 4.3% |
| Ipca Laboratories Ltd. | Healthcare | Equity | 4.0% |
| Dr. Reddy's Laboratories Ltd. | Healthcare | Futures | 3.7% |
| Sanofi India Ltd. | Healthcare | Equity | 3.3% |
ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund Direct Growth is a Equity Mutual Fund Scheme launched by ICICI Prudential Mutual Fund. This scheme was made available to investors on 15 Jun 2018. Ihab Dalwai, Priyanka Khandelwal is the Current Fund Manager of ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹1,988 Cr and the Latest NAV as of 23 Oct 2020 is ₹16.37.
The ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund Direct Growth is rated High risk. Minimum SIP Investment is set to 100. Minimum Lumpsum Investment is 5000. Exit load of 1% if redeemed within 15 days.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.